ADAR1 Capital Management’s CorMedix CRMD Stock Holding History

ADAR1 Capital Management’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-175,000	Closed	-$2.16M	–	231
2025 Q2	$2.16M	Buy	+175,000	New	+$1.93M	0.33%	52

Other funds holding CRMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ADAR1 Capital Management's CRMD Position: Q3 2025 in Review

ADAR1 Capital Management sold out of CorMedix (CRMD) in Q3 2025, closing a stake of 175,000 shares — an estimated $2.16M sold.

ADAR1 Capital Management first reported a position in CRMD in Q2 2025 and held it in 1 quarter. The position peaked at $2.16M in Q2 2025. 190 funds tracked by Wall St. Rank hold CRMD as of Q3 2025.

ADAR1 Capital Management reported no remaining CorMedix position as of Q3 2025 after selling out during the quarter.
ADAR1 Capital Management sold 175,000 CorMedix shares in Q3 2025, an estimated $2.16M.
ADAR1 Capital Management first reported a position in CorMedix in Q2 2025 and held it in 1 quarter.
ADAR1 Capital Management's CorMedix position peaked at $2.16M in Q2 2025.
190 funds tracked by Wall St. Rank held CorMedix as of Q3 2025.

Based on ADAR1 Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.